Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection GlobeNewswire November 04, 2025 Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026 […]

Stewards Inc. Announces $10 Million Private Placement With Dolomite Foundation to Advance Digital Asset Strategy Transaction supports Stewards' Digital Asset Treasury initiative and the company's diversified financial platform spanning private credit, real assets and digital finance GlobeNewswire November 04, 2025 FORT LAUDERDALE, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — via IBN – Stewards Inc. (OTC:

Lancaster Resources Expands Footprint in James Bay with Additional Claims at Lac Iris Polymetallic Project GlobeNewswire November 04, 2025 VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF) (“Lancaster” or the “Company“), is pleased to announce that it has acquired a 100% interest in additional mineral claims, “Lac

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) GlobeNewswire November 04, 2025 LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 04, 2025 TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A

Colliers Reports Third Quarter Results GlobeNewswire November 04, 2025 Solid momentum across all segments, tracking well to 2025 outlook Third quarter and year to date operating highlights: Three months ended Nine months ended September 30 September 30 (in millions of US$, except EPS) 2025 2024 2025 2024 Revenues $ 1,463.1 $ 1,179.1 $ 3,951.9 $

First Watch Restaurant Group, Inc. Reports Q3 2025 Financial Results GlobeNewswire November 04, 2025 Same-restaurant sales growth of 7.1%Total revenues increased 25.6%Net income of $3.0 million and Adjusted EBITDA of $34.1 million21 new system-wide restaurants opened in 14 states BRADENTON, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First

Dave Reports Third Quarter 2025 Financial Results GlobeNewswire November 04, 2025 Record Q3 Revenue of $150.8 Million, up 63% Y/Y Driven by Accelerating MTM Growth and Record ARPU Record Q3 ExtraCash Monetization Rate Net of Losses of 4.8%, up 45bps Y/Y as Originations Grew 49% to over $2 Billion; Improving Credit Performance Supported Further Net

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences GlobeNewswire November 04, 2025 ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results GlobeNewswire November 04, 2025 Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024 Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per